Serotonin noradrenaline reuptake inhibitors: Logical evolution of antidepressant development

International Journal of Psychiatry in Clinical Practice

Volumn 10, Issue SUPPL. 2, 2006, Pages 5-11

  Montgomery, Stuart ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antidepressant efficacy; Duloxetine; Milnacipran; Side effects; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; NORADRENALIN; PAROXETINE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; EUROPE; HUMAN; HYPERHIDROSIS; IN VITRO STUDY; IN VIVO STUDY; INSOMNIA; META ANALYSIS; NAUSEA; NEUROTRANSMISSION; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; SOMNOLENCE; VERTIGO; XEROSTOMIA;

EID: 33646675595     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500600637049     Document Type: Article

References (43)

1. Wong DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sci 1995;57:411-41.
2. Cookson J. Side-effects of antidepressants. Br J Psychiatry 1993;20(Suppl July):20-4.
3. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatry 1998;44:77-87.
4. Burrows GD, Maguire KP, Norman TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 1998;59(Suppl 14):4-7.
5. Nelson JC. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry 1999;46:1301-8.
6. Danish University Antidepressant Group. Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berlin) 1986;90:131-8.
7. Danish University Antidepressant Group. Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-99.
8. Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238-49.
9. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depression Anxiety 1998;7(Suppl 1):11-7.
10. Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized study. Biol Psychiatry 2004;55:296-300.
11. Koch S, Hemrick-Luecke SK, Thompson LK, et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 2003;45:935-44.
12. Millan MJ, Lejeune F, Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: Relevance to the actions of antidepressant agents. J Psychopharmacol 2000;14:114-38.
13. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A metaanalysis. Br J Psychiatry 2002;180:396-404.
14. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-94.
15. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-43.
16. Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:57-71.
17. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41.
18. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-6.
19. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64.
20. Murdoch D, Keam SJ. Escitalopram: A review of its use in the management of major depressive disorder. Drugs 2005;65:2379-404.
21. Montgomery SA. Escitalopram and depression. 2nd ed. London: Science Press Ltd; 2005.
22. Lopez-Ibor J, Guelfi JD, Pletan Y, et al. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996;11(Suppl 4):41-6.
23. Sechter D, Vandel P, Weiller E, et al. A comparative study of milnacipran and paroxetine in outpatients with major depression. J Affect Disord 2004;83:233-6.
24. Clerc G, Milnacipran/Fluvoxamine Study Group. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: A comparison with fluvoxamine. Int Clin Psychopharmacol 2001;16:145-51.
25. Montes JM, Ferrando L, Saiz-Ruiz J. Remission in major depression with two antidepressant mechanisms: Results from a naturalistic study. J Affect Disord 2004;79:229-34.
26. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-99.
27. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: A placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-70.
28. Thase ME, Lu Y, Joliat MJ, et al. Remission in placebo-controlled trials of duloxetine with an SSRI comparator. Poster presented at the American Psychiatric Association Meeting, San Francisco, CA, 2003.
29. Stahl SM, Grady MM, Moret C, et al. SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10:732-47.
30. Nemeroff CB, Entsuah R, Willard LB, et al. Comprehensive pooled analysis of remission data: Venlafaxine vs. SSRIs (COMPARE). Poster presented American Psychiatric Association Meeting, San Francisco, CA, 2003.
31. Perahia D, Pritchett YL, Lee TC et al. Comparing duloxetine and venlafaxine in the treatment of major depressive disorder using a global benefit-risk approach. Abstracts of NCDEU 2005; poster 1-14 [http://www.nimh. nih.gov/ncdeu/2005abstracts.pdf].
32. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999;57:507-33.
33. Angst J. Course of mood disorders: A challenge to psychopharmacology. Clin Neuropharmacol 1992;15(Suppl 1, Pt A):444-5.
34. Keller MB. The naturalistic course of anxiety and depressive disorders. Clin Neuropharmacol 1992;15(Suppl 1, Pt A):171-3.
35. Surtees PG, Barkley C. Future imperfect: the long-term outcome of depression. Br J Psychiatry 1994;164:327-41.
36. Maj M, Veltro F, Pirozzi R, et al. Pattern of recurrence of illness after recovery from an episode of major depression: A prospective study. Am J Psychiatry 1992;149:795-800.
37. Montgomery SA, Entsuah R, Hackett D, et al. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry 2004;65:328-36.
38. Rouillon F, Warner B, Pezous N, et al. Milnacipran efficacy in the prevention of recurrent depression: A 12-month placebo-controlled study. Int Clin Psychopharmacol 2000;15:133-40.
39. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217-22.
40. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189-95.
41. Mallinckrodt CH, Goldstein DJ, Detke MJ, et al. Duloxetine: A new treatment for the emotional and physical symptoms of depression. Prim Care Companion J Clin Psychiatry 2003;5:19-28.
42. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41.
43. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: A pooled analysis of patients with depression. Biol Psychiatry 2002;52:1166-74.